Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bolder BioTechnology has been awarded a $121,844 phase I small business innovation research (SBIR) grant from the US National Institutes of Health. The grant provides funds to optimize the pharmacological properties of a human enzyme capable of inactivating toxic organophosphorus nerve agents such as Soman, Sarin and VX.
Subscribe to our email newsletter
The optimized butyrylcholinesterase protein may have applications in biodefense as a bioscavenger protein for detoxifying nerve agents, and as a treatment for patients with cocaine or heroin drug overdoses.
The SBIR program provides research support to small businesses to discover and develop innovative biomedical products for the treatment of serious unmet medical needs. Companies that successfully meet the goals of the phase I grant are eligible to apply for an additional $750,000 in phase II grant support to continue their product development efforts.
Bolder BioTechnology uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of a range of disease in the areas of hematopoietic and endocrine disorders, cancer, and infectious diseases.
In May, the company was awarded a $99,000 phase I SBIR grant from the US National Institutes of Health supporting research into a human protein able to stimulate the body’s immune system to fight infections. This protein may prove useful in viral infections, immunodeficiencies and various cancers.